// App-Quantinova.ai

PO‐080 : Long‐term follow‐up with GS‐4059, a selective irreversible BTK inhibitor, in patients with relapsed and refractory chronic lymphocytic leukemia

Researchers

Presenter

  • HS Walter

Principal Investigators

  • S Jayne

  • SA Rule

  • G Cartron

  • F Morschhauser

  • C Fegan

  • Y Yang

  • S Mitra

  • MJS Dyer

  • G Salles

Medical Centers

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, United Kingdom

  • Department of Clinical Hematology and Unite Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), CHRU, Montpellier, France

  • Department of Clinical Hematology, Centre Hospitalier Universitaire, Universite de Lille, Lille, France

  • Cardiff CLL Research Group, School of Medicine, Heath Park, Cardiff University, Cardiff, Wales, United Kingdom

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • Hospices Civils de Lyon, Centre Hospitalier Lyon Sud - Service dEndocrinologie, Pierre Benite, France

Locations

  • United Kingdom

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • N/A

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • Bruton tyrosine kinase

  • Phospholipase C-gamma-2

  • Tumor protein p53

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • L-Tyrosine

  • TP53

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT01659255

  • NCT02457559

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved